Moreno-Olmedo, ElenaSuárez-Gironzini, VladimirPérez, ManuelFiligheddu, TeresaMínguez, CristinaSanjuan-Sanjuan, AlbaGonzález, José ARivas, DanielGorospe, LuisLarrea, LuisLópez, Escarlata2023-02-092023-02-092021-01-27http://hdl.handle.net/10668/17057Since the outbreak of coronavirus disease 2019 (COVID-19) pandemic, healthcare systems have focused their efforts into finding a treatment to avoid the fatal outcomes of severe acute respiratory syndrome due to coronavirus‑2 (SARS-CoV-2). Benefits and risks of systemic treatments remain unclear, with multiple clinical trials still ongoing. Radiotherapy could play a role in reducing the inflammatory response in the lungs and relieve life-threatening symptoms. We designed a prospective study of Ultra-Low Doses of Therapy with Radiation Applied to COVID-19 (ULTRA-COVID) for patients who suffer pneumonia, are not candidates for invasive mechanical ventilation and show no improvement with medical therapy. We present the preliminary results of two patients diagnosed with COVID-19 pneumonia treated with ULTRA-COVID. After one radiotherapy session, significant clinical response and a good radiological response was observed in both cases, resulting in both patients being discharged from hospital in less than 2 weeks after radiation treatment. Preliminary clinical and radiological results suggest a potential benefit of treating COVID-19 pneumonia with ULTRA-COVID. ClinicalTrials.gov Identifier: NCT04394182.enCOVID-19 pneumonitisCytokine stormInflamatory responseRadiationSARS-CoV-2AgedAged, 80 and overCOVID-19FemaleHumansMalePreliminary DataProspective StudiesRadiotherapyRadiotherapy DosageSARS-CoV-2Treatment Outcomeresearch article33502567open access10.1007/s00066-020-01743-41439-099XPMC7839288https://link.springer.com/content/pdf/10.1007/s00066-020-01743-4.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839288/pdf